Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence

Ricky D Turgeon; Shelley Zieroth; David Bewick; Chi-Ming Chow; Brian Clarke; Simone Cowan; Christopher B Fordyce; Anne Fournier; Kenneth Gin; Anil Gupta; Sean Hardiman; Simon Jackson; Benny Lau; Howard Leong-Poi; Samer Mansour; Ariane Marelli; Ata Rehman Quraishi; Idan Roifman; Marc Ruel; John Sapp; Gurmeet Singh; Gary Small; Sean Virani; David A Wood; Andrew Krahn

doi:10.1016/j.cjca.2020.05.033

Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence

Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.

Authors

Ricky D Turgeon¹, Shelley Zieroth², David Bewick³, Chi-Ming Chow⁴, Brian Clarke⁵, Simone Cowan⁶, Christopher B Fordyce⁶, Anne Fournier⁷, Kenneth Gin⁶, Anil Gupta⁸, Sean Hardiman⁹, Simon Jackson¹⁰, Benny Lau⁶, Howard Leong-Poi⁴, Samer Mansour¹¹, Ariane Marelli¹², Ata Rehman Quraishi¹⁰, Idan Roifman¹³, Marc Ruel¹⁴, John Sapp¹⁰, Gurmeet Singh¹⁵, Gary Small¹⁴, Sean Virani⁶, David A Wood⁶, Andrew Krahn⁶

Affiliations

¹ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: [email protected].
² University of Manitoba, Winnipeg, Manitoba, Canada.
³ New Brunswick Heart Centre, Saint John, New Brunswick, Canada.
⁴ Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
⁵ Libin Cardiovascular Institute, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.
⁶ Centre for Cardiovascular Innovation, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
⁷ Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Québec, Canada.
⁸ Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.
⁹ Cardiac Services British Columbia, Provincial Health Services Authority, Vancouver, British Columbia, Canada.
¹⁰ Queen Elizabeth II Health Sciences Center, Division of Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada.
¹¹ Department of Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.
¹² McGill University Health Center, Department of Medicine, McGill University, Montréal, Québec, Canada.
¹³ Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
¹⁴ University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
¹⁵ Mazankowski Alberta Hearth Institute, Division of Cardiac Surgery, Departments of Critical Care Medicine and Surgery, University of Alberta, Edmonton, Alberta, Canada.

No abstract available

Publication types

Editorial

MeSH terms

Angiotensin II Type 1 Receptor Blockers / pharmacology*
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Betacoronavirus / physiology*
COVID-19
Coronavirus Infections* / epidemiology
Coronavirus Infections* / therapy
Coronavirus Infections* / virology
Heart Failure / drug therapy*
Humans
Hypertension / drug therapy*
Pandemics*
Patient Care Management
Peptidyl-Dipeptidase A / metabolism
Pneumonia, Viral* / epidemiology
Pneumonia, Viral* / therapy
Pneumonia, Viral* / virology
Practice Guidelines as Topic
Renin-Angiotensin System* / drug effects
Renin-Angiotensin System* / physiology
SARS-CoV-2
Virus Internalization / drug effects

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2